Children's hematological malignancies mainly include various types of leukemia, malignant lymphoma, and multiple myeloma that occur in children. With the improvement of medical technology, the overall survival rate of hematological malignancies in children is increasing. However, there are still many deaths from hematological malignancies in children every year and tumor recurrence or treatment-related complications are the main causes. It is gratifying that with the emergence of immunotherapies, the therapeutic effectiveness of refractory childhood hematological malignancies has been remarkably improved. These anti-tumour immunotherapies aim to artificially enhance the body's immune function and rely on immune system to kill cancer cells. Development of chimeric antigen receptor (CAR) T-cell therapies for patients with hematological malignancies is a recent example of this outstanding progress. Recently, Hundreds of clinical trials regarding CAR T therapy have been registered. Although CAR T and other immunotherapy techniques have made plenty of achievements in the treatment of hematological malignancies, there are still many problems to be resolved. For example, more investigations are still needed in the following areas: (1) how to further treat patients who relapse after immunotherapy, (2) how to improve treatment strategy of immunotherapy tolerant patients, and (3) how to avoid the side effects of immunotherapy.
The Research Topic aims to promote the academic exchange and experience sharing of immunotherapy for hematological malignancies in children. Firstly, we would like to invite our colleagues to contribute some guiding information for the diagnosis and treatment of all children with hematological malignancies. Moreover, we also like researchers to discuss the current situation, existing problems and development trend of immunotherapy in the treatment of children's hematological malignancies. Finally, the Research Topic seeks to provide a platform for the discussion of prediction of the effect of immunotherapy, the prevention of complications, the enhancement of efficiency and the exploration of new targets.
We would like submissions of Original Articles, Systematic Review, in the following subtopics, but not limited to:
• Construction of a prediction method for the Immunotherapeutic effect or prognosis in children's hematological malignancies.
• Screening of new targets for CAR T or other immunotherapy of hematological malignancies in children.
• Exploration of the Immunotherapeutic tolerance mechanism in children's hematological malignancies.
• Evaluation of immune microenvironment of hematological malignancies in children.
• All other studies related to immunotherapy or hematological malignancies in children.
Children's hematological malignancies mainly include various types of leukemia, malignant lymphoma, and multiple myeloma that occur in children. With the improvement of medical technology, the overall survival rate of hematological malignancies in children is increasing. However, there are still many deaths from hematological malignancies in children every year and tumor recurrence or treatment-related complications are the main causes. It is gratifying that with the emergence of immunotherapies, the therapeutic effectiveness of refractory childhood hematological malignancies has been remarkably improved. These anti-tumour immunotherapies aim to artificially enhance the body's immune function and rely on immune system to kill cancer cells. Development of chimeric antigen receptor (CAR) T-cell therapies for patients with hematological malignancies is a recent example of this outstanding progress. Recently, Hundreds of clinical trials regarding CAR T therapy have been registered. Although CAR T and other immunotherapy techniques have made plenty of achievements in the treatment of hematological malignancies, there are still many problems to be resolved. For example, more investigations are still needed in the following areas: (1) how to further treat patients who relapse after immunotherapy, (2) how to improve treatment strategy of immunotherapy tolerant patients, and (3) how to avoid the side effects of immunotherapy.
The Research Topic aims to promote the academic exchange and experience sharing of immunotherapy for hematological malignancies in children. Firstly, we would like to invite our colleagues to contribute some guiding information for the diagnosis and treatment of all children with hematological malignancies. Moreover, we also like researchers to discuss the current situation, existing problems and development trend of immunotherapy in the treatment of children's hematological malignancies. Finally, the Research Topic seeks to provide a platform for the discussion of prediction of the effect of immunotherapy, the prevention of complications, the enhancement of efficiency and the exploration of new targets.
We would like submissions of Original Articles, Systematic Review, in the following subtopics, but not limited to:
• Construction of a prediction method for the Immunotherapeutic effect or prognosis in children's hematological malignancies.
• Screening of new targets for CAR T or other immunotherapy of hematological malignancies in children.
• Exploration of the Immunotherapeutic tolerance mechanism in children's hematological malignancies.
• Evaluation of immune microenvironment of hematological malignancies in children.
• All other studies related to immunotherapy or hematological malignancies in children.
